MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine

Cancer Treat Rev. 2016 Sep;49:57-64. doi: 10.1016/j.ctrv.2016.07.007. Epub 2016 Jul 29.

Abstract

This article will review the impact of the recently developed MassARRAY technology on our understanding of cancer biology and treatment. Analysis of somatic mutations is a useful tool in selecting personalized therapy, and for predicting the outcome of many solid tumors. Here, we review the literature on the application of MassARRAY technology (Sequenom Hamburg, Germany) to determine the mutation profile of solid tumors from patients. We summarize the use of commercially available panels of mutations - such as OncoCarta™ or other combinations - and their concordance with results obtained by using other technologies, such as next generation sequencing.

Keywords: MassARRAY technology; OncoCarta panel v1.0; Solid tumors; Somatic mutation profile.

Publication types

  • Review

MeSH terms

  • High-Throughput Nucleotide Sequencing
  • Humans
  • Mutation
  • Neoplasms / genetics*
  • Oligonucleotide Array Sequence Analysis
  • Oncogenes / genetics*
  • Precision Medicine